Lund, Sweden, May 25, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted and selected as a late-breaking abstract for an oral presentation at the upcoming American Transplant Congress (ATC) in Boston, June 22, 2026. Read more…
Progress for our clients in the clinic this week, with Mestag Therapeutics dosing the first patient in their STARLYS clinical trial and STORM Therapeutics to present data on its dose escalation study at ASCO later this month. More good news, as Hansa Biopharma entered a multi-million-Euro licensing agreement with SERB S.A. Bring on the bank […]
The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region Significantly enhances Hansa’s financial position, ensuring a robust U.S. launch and provides path to profitability, subject to US approval SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization Lund, […]
Lund, Sweden, 18 May. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, be participating in a panel discussion titled “Scaling Success: Key Drivers for Growing Nordic Biotechs” at the LSX Nordic Congress, in Copenhagen, at 13:10 CEST on Tuesday 19 , 2026. Read more…
Riding the wave of BioEquity, it has been another busy week for Optimum’s clients. Hansa Biopharma, Poolbeg Pharma and Resolution Therapeutics are all taking to the stage across Europe and the US. Optimum’s own Stephen Adams will be chairing a panel at LSX Nordic next week after yet another fascinating Hot Topic – this time […]
